Non-Invasive Prenatal Testing (NIPT) Market, By Product Type (Devices, Consumables, and Others), By Techniques (cfDNA, Biochemical Screening Tests, and Ultrasound Detection), By Application (Trisomy, Microdeletion syndrome, and Others), By End-User (Diagnostic Laboratories, Hospitals, and Cell DNA screening), and By Region - Trends, Analysis, and Forecast till 2030

Non-invasive prenatal testing (NIPT) market accounted for USD 4.3 Billion in 2019 and is estimated to be USD 11.8 Billion by 2029 and is anticipated to register a CAGR of 11.9%.

A Non-Invasive Prenatal Testing (NIPT) is a screening test to identify if the unborn child/fetus is at risk for a Noninvasive prenatal testing (NIPT), sometimes called noninvasive prenatal screening (NIPS), is a method of determining the risk of a fetus being born with certain genetic abnormalities. This test analyzes small pieces of DNA circulating in a pregnant woman's blood. NIPT is used to detect chromosomal disorders caused by the presence of an extra or missing copy of a chromosome (aneuploidy). Down syndrome, Edwards’s syndrome, Patau syndrome etc.

The test is done using a blood sample which reduces the risk of miscarriage during the test to absolutely zero and has the ability to detect many disorders within 10 weeks of pregnancy, much earlier than any other prenatal diagnostic tests. NIPT has been ranked as the most successful, sensitive, and most accurate test, making it the most preferred test. With increasing percentage of pregnancies among women of advanced age, there is increasing demand for prenatal genetic counseling that helps in predicting the risk of chromosomal abnormalities of the fetus depending on age, thereby fueling the growth of the non-invasive prenatal testing market.

High risk of chromosomal abnormalities with increasing maternal age

Maternal age plays an important role in child health and delay in maternal age can lead to various risks such as reduced fertility, high blood pressure and increased risk of miscarriage, stillbirth and maternal death. Furthermore, increasing maternal age may increase the risk of genetic disorders in babies as a result of improper chromosome segregation. Resulting malformations in babies can include microcephaly; short neck; upper slanting eyes; poor muscle tone; and heart, bowel and respiratory problems. There is a growing demand for early screening of expectant mothers, to detect genetic abnormalities caused by improper chromosome segregation. Hence, non-invasive prenatal testing is the safest one, thus driving the market.

Restraints:

Reliability of test results, especially in obese women

A non-invasive prenatal test using maternal blood, which is the source of fetal DNA. However, the amount of fetal fraction in the blood is affected by the mother's weight. It has been reported that the plasma of obese women contains less traces of fetal DNA and therefore may not provide suitable results for analyzing trisomy and other disorders. Thus, non-invasive prenatal testing is not a standardized test. Hence, this factor acts as a restraining factor for the global non-invasive prenatal testing (NIPT) market.

Technological advancement

Advances in modern molecular technology and the discovery of cell-free fetal DNA in maternal plasma have led to new screening methods for fetal chromosomal aneuploidies. With increasing throughput and low cost, NGS technology has paved the way for the detection of chromosomal abnormalities with cffDNA analysis. Growing awareness of the benefits of non-invasive methods has led to a steady increase in the development of advanced technologies for NIPT. Many companies continue to focus on developing highly advanced screening technologies that are highly sensitive and accurate for early detection of genetic disorders in children. Manufacturers are mainly focusing on the development of advanced non-invasive prenatal tests and entering into strategic partnerships and collaborations to strengthen their position in the market.

The global non-invasive prenatal testing (NIPT) market is segmented based on product type, techniques, application, end-user, and region. Depending upon the product type, the market is segmented into devices, consumables, and others. Based on the techniques, the global non-invasive prenatal testing (NIPT) market is segmented into cfDNA, biochemical screening tests, and ultrasound detection. By application, the market is segmented into trisomy, microdeletion syndrome, and others. The end-user is segmented into diagnostic laboratories, hospitals, and cell DNA screening. The largest share of this application segment is primarily attributed to factors such as increasing incidence of trisomy in babies associated with advancing maternal age in recent years.

Regional Insights:

On region the Global Non-Invasive Prenatal Testing (NIPT) Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global non-invasive prenatal testing (NIPT) market in terms of revenue due to the increasing availability of the high R&D investment and the availability of technologically advanced healthcare research framework, the development of WGS in the region is also expected to serve as a critical factor for the growth of North America NIPT market throughout the forecast period. Followed by Europe and Asia and the reason being the developing healthcare infrastructure, rising awareness programs & conferences, and rising focus of prominent players on expanding their presence in these regions.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global non-invasive prenatal testing (NIPT) market is segmented based on product type, techniques, application, end-user, and region

Global Non-Invasive Prenatal Testing (NIPT) Market, By Product Type:

• Devices
• Consumables
• Others

Global Non-Invasive Prenatal Testing (NIPT) Market, By Techniques:

• cfDNA
• Biochemical Screening Tests
• Ultrasound Detection

Global Non-Invasive Prenatal Testing (NIPT) Market, By Application:

• Trisomy
• Microdeletion syndrome
• Others

Global Non-Invasive Prenatal Testing (NIPT) Market, By End User:

• Diagnostic Laboratories
• Hospitals
• cell DNA screening

Global Non-Invasive Prenatal Testing (NIPT) Market, By Region:

• North America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • U.S.
  • Canada

The key players operating the Global Non-Invasive Prenatal Testing (NIPT) Market includes Sequenom, Roche (Ariosa Diagnostics); Natera, LabCorp, BGI Genomics; Quest Diagnostics, Illumina, Laboratory Corporation of America Holdings, Yourgene Health, and Berry Genomics. For instance, in July 2022, Yourgene Health focused on bolstering its core business to fill COVID-testing void, Manchester genomic testing specialist Yogen Health is set to fill its Covid-testing void by expanding its core offering, linked to further international growth.

• Sequenom
• Roche (Ariosa Diagnostics)
• Natera
• LabCorp
• BGI Genomics
• Quest Diagnostics
• Illumina
• Laboratory Corporation of America Holdings
• Yourgene Health
• Berry Genomics.